Dr. José Antonio Mata-Marín
“Patients in Mexico’s public system deserve clinical information that is as rigorous as the research that produced it. My role is to make sure every piece of guidance SunnyPharma publishes meets that standard.”
Clinical Practice. Research. Patient Education.
Dr. José Antonio Mata-Marín is an infectious disease specialist at the Hospital de Infectología “La Raza” National Medical Center, part of the Instituto Mexicano del Seguro Social (IMSS) in Mexico City. The Hospital de Infectología “La Raza” is one of Mexico’s principal public-system referral centers for HIV and infectious disease care, serving thousands of patients through Mexico’s social security system.
Dr. Mata-Marín’s clinical and research work focuses on HIV care, HIV/HCV and HIV/HBV co-infection, antiretroviral therapy outcomes, and infectious disease epidemiology in Mexican patient populations. He has been first author on multiple peer-reviewed publications addressing transmission risk factors, treatment outcomes, and metabolic effects of modern antiretroviral regimens — including the 2025 MICTLAN trial, a head-to-head comparison of bictegravir-based and dolutegravir-based regimens published in AIDS, the official journal of the International AIDS Society.
His work consistently centers on the realities of the Mexican public health system: how treatment outcomes look in IMSS clinical settings, how transmission patterns affect Mexican patient populations, and how international treatment guidelines translate to Mexican clinical practice. This is the perspective he brings to his review work for SunnyPharma — clinical accuracy grounded in the actual conditions Mexican patients face.
For SunnyPharma, Dr. Mata-Marín reviews articles on HIV treatment, HIV/HCV co-infection, antiretroviral therapy, and related topics for clinical accuracy. Every article he reviews carries his named byline alongside the article’s writer. His review covers clinical claims, dosing information, drug interaction guidance, and alignment with current international treatment guidelines as well as Mexican Secretaría de Salud recommendations where relevant.
Patients in Mexico’s public system deserve clinical information that is as rigorous as the research that produced it. My role is to make sure every piece of guidance SunnyPharma publishes meets that standard.
Selected Peer-Reviewed Publications
Dr. Mata-Marín has authored or co-authored multiple peer-reviewed publications in international journals. Selected first-author works include:
-
Incidence of Metabolic Syndrome in People with HIV without Experience to Antiretroviral Therapy who Start Dolutegravir-Based Regimen Compared with Bictegravir-Based Regimen after 48 Weeks (MICTLAN trial)View on PubMed →
-
Risk Factors for HCV Transmission in HIV-Positive Men Who Have Sex with Men in MéxicoView Publication →
-
Mexican Patients with HIV Have a High Prevalence of Vertebral FracturesView on PubMed →
-
Effectiveness of Pegylated Interferon Alfa Plus HAART in HIV/HBV Treatment-Naïve Coinfected PatientsView Publication →
-
Prevalence of HIV Drug-Resistance Mutations in HIV-Infected Mexican Patients Heavily Experienced to Antiretroviral TherapyView Publication →
-
Complete publication archive available via PubMed and ORCIDView ORCID Profile →
Editorial Standards & Independence
All content reviewed by Dr. Mata-Marín for SunnyPharma is evaluated against current evidence-based clinical standards, including the U.S. Department of Health and Human Services HIV treatment guidelines, the International Antiviral Society–USA Panel recommendations, and current Mexican Secretaría de Salud HIV guidelines where relevant to Mexican patient populations.
Dr. Mata-Marín’s primary clinical and research affiliation is with the Hospital de Infectología “La Raza,” IMSS, Mexico City. His review work for SunnyPharma is independent of his IMSS clinical role. SunnyPharma articles he reviews are not statements of IMSS clinical policy, and his clinical judgment in his SunnyPharma role is independent of any pharmaceutical manufacturer.
Last credentials verified: April 2026 | Editorial oversight: Dr. Neha Mishra, MBBS, MD and Dr. Jürgen Epple